Vivacta is a young IVD company based on broad and strong IP. With opportunities to use the technology widely across immunoassay as well as molecular diagnostics markets, the company believes that speed of exploitation is important. To facilitate this, we intend to partner with large diagnostic companies that can take the technology to market.

We are privately held with Venture Capital funding from Spark Ventures, HBM BioVentures and AGF Private Equity. If you would like to establish contact for possible future funding click this link invest@vivacta.com